It is important to identify the most important factors governing a successful attack of NSCLC by CD8+ T cells as illustrated by the facts that a) more than 40% of NSCLC patients respond to checkpoint inhibitor therapy [5–7]; and b) especially those patients are likely to respond in whom the tumor has generated neo antigens for CD8+ T cells [31]. Here, CD8A is linked to neoplasm.